

T07E80"659E4660




FIG. 1




FIG. 2




FIG. 3

09943659 083101




FIG. 4




FIG. 5




FIG. 6

Experimental Protocol

5TGM1




Figure 7

Serum IgG₂ levels in 5TGM1-bearing mice

IgG₂ (mg/ml) n=6




Figure 8

Tumor Volume in Bone

Treatment/no treatment (%)
n=6-12




Figure 9

EFFECT OF PS/2 mAb TREATMENT
ON SPLEEN WEIGHT




Figure 10

EFFECT OF PS/2 TREATMENT ON SPLENOCYTES
IN MICE WITH 5TGM1 MYELOMA





Figure 11

EFFECT OF PS/2 mAb TREATMENT ON SPLENOCYTE FACS PROFILE


DISEASE FREE



File: do111700.077 Acquisition Date: 17-Nov-00
 Gate: G1 Gated Events: 9624
 Total Events: 10707 Quad Location: 523, 25

Quad	Events	% Gated	% Total	X Mean	Y Mean
UL	9499	98.70	88.72	37.11	1120.67
UR	3	0.03	0.03	5084.96	773.52
LL	122	1.27	1.14	31.88	11.09
LR	0	0.00	0.00	***	***


UNTREATED



File: do111700.100 Acquisition Date: 17-Nov-00
 Gate: G1 Gated Events: 9526
 Total Events: 11100 Quad Location: 523, 25

Quad	Events	% Gated	% Total	X Mean	Y Mean
UL	4959	52.06	44.68	84.30	1023.41
UR	1388	14.57	12.50	2377.81	704.20
LL	2163	22.71	19.49	50.53	6.64
LR	1016	10.67	9.15	3619.03	4.05


PS/2 TREATED



File: do111700.120 Acquisition Date: 17-Nov-00
 Gate: G1 Gated Events: 9561
 Total Events: 10934 Quad Location: 523, 25

Quad	Events	% Gated	% Total	X Mean	Y Mean
UL	7868	82.29	71.96	58.00	1139.33
UR	310	3.24	2.84	1922.82	897.47
LL	1171	12.25	10.71	42.10	8.17
LR	212	2.22	1.94	3153.17	3.62

rat IgG2b TREATED



File: do111700.137 Acquisition Date: 17-Nov-00
 Gate: G1 Gated Events: 9595
 Total Events: 10970 Quad Location: 523, 25

Quad	Events	% Gated	% Total	X Mean	Y Mean
UL	4910	51.17	44.76	84.95	975.19
UR	1384	14.42	12.62	1937.36	694.49
LL	1704	17.76	15.53	48.67	7.00
LR	1597	16.64	14.56	3266.15	2.68

Figure 12

EFFECT OF PS/2 mAb TREATMENT ON
SPLEEN TUMOR BURDEN




Figure 13

EFFECT OF PS/2 mAB TREATMENT ON BONE MARROW CELLS
IN MICE WITH 5TGM1 MYELOMA




Figure 14

EFFECT OF PS/2 TREATMENT ON BONE MARROW TUMOR BURDEN
mlgG2b POSITIVE CELLS




Figure 15


EFFECT OF PS2 mAb TREATMENT
ON STGM1 CELLS IN THE BLOOD

Figure 16

EFFECT OF PS/2 TREATMENT ON BLOOD CHEMISTRY




Figure 17

T0TE810" 65944560

EFFECT OF PS/2 mAb ON
CIRCULATION mIgG2b LEVELS




Figure 18

C57Bl/KaLwRij MULTIPLE MYELOMA MODEL
ACUTE TREATMENT PROTOCOLS




Figure 19

ACUTE TREATMENT MODEL

EFFEKT OF PS2 TREATMENT ON IgG2b POSITIVE CELLS




Figure 20

EFFECT OF ANTI VLA-4 ANTIBODY PS/2
ON TUMOR BURDEN IN SPLEEN




Figure 21

EFFECT OF 6 DAYS OF PS/2 TREATMENT




Figure 22

EFFECT OF 6 DAYS OF PS2 TREATMENT ON BONE MARROW CELLS





Figure 23

CS7/B1KaLwRaj MODEL OF MULTIPLE MYELOMA COMBINATION TREATMENT WITH PS1/2 AND MELPAHLAN



**5TGMI CELLS (1E6) WERE INJECTED (I.V.) ON DAY 0
EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 20 AND DAY 27**

卷之三

GROUPS N=3/GROUP

DISEASE FREE CONTROL
UNTREATED MYELOMA CONTROL
MELPHALAN TREATMENT—100 MICROGRAMS/INJECTION
PS2 TREATMENT—100 MICROGRAMS/INJECTION
MELPHALAN AND PS2
MELPHALAN AND IgG2b ISOTYPE CONTROL

Figure 24

EFFECT OF TREATMENT ON mIgG2b PLASMA LEVELS




Figure 25

EFFECT OF TREATMENT ON MYELOMA CELLS AT DAY 27




Figure 26

EFFECT OF TREATMENT ON TUMOR BURDEN AT DAY 27





Figure 27

	Day 20	day 27
	PS/2 Plasma levels	PS/2 Plasma levels
8-PS/2	none detected	none detected
9-PS/2	none detected	none detected
10-PS/2	none detected	none detected
11-melphalan+PS/2	none detected	none detected
12-melphalan+PS/2	3.7 μ g/ml	none detected
13-melphalan+PS/2	none detected	none detected

Figure 28

C57/B1K/LwRaj MODEL OF MULTIPLE MYELOMA
 PS/2 AND ANTI VLA4 SMALL MOLECULE
 LONG TERM TREATMENT



STGMI CELLS (1E6) INJECTED(I.V.) ON DAY 0
 EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 20

GROUPS N=2/GROUP
 DISEASE FREE CONTROL
 UNTREATED MYELOMA CONTROL
 PS/2 ~100 micrograms/injection
 Sm. Mol. 8809-3 mg/kg, 0.3 mg/kg or 0.03 mg/kg
 Sm. Mol. 9257 CONTROL -- 3 mg/kg

EFFECT OF LONG TERM TREATMENT ON MYELOMA CELLS




Figure 30

EFFECT OF LONG TERM TREATMENT ON TUMOR BURDEN





Figure 31

C57/BlKALwRaj MODEL OF MULTIPLE MYELOMA
 PS/2 AND ANTI VLA4 SMALL MOLECULE
 ACUTE TREATMENT



STGMI CELLS (1E6) INJECTED(I.V.) ON DAY 0
 PS/2 WAS GIVEN ON DAYS 15,16,17,18,19 AND 20
 SMALL MOLECULE WAS GIVEN ON DAYS 15, 16 AND 17
 EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 21

GROUPS	N=2/GROUP
DISEASE FREE CONTROL	
UNTREATED MYELOMA CONTROL	
PS/2 -100 micrograms/injection	
8809-3 mg/kg, 0.3 mg/kg or 0.03 mg/kg	
9257 CONTROL - 3 mg/kg	

Figure 32

EFFECT OF ACUTE TREATMENT ON MYELOMA CELLS





Figure 33

EFFECT OF ACUTE TREATMENT ON TUMOR BUREN

SPLEEN



BONE MARROW




Figure 34

Experimental Protocol




Figure 35

Inhibition of Hindleg Paralysis




Figure 36